C

CRISPR Therapeutics

Develops gene-editing therapies using CRISPR

Executive Director of Clinical Development

Full-Time
$290k - $315k/yr+ Bonus + Equity
Expert
MD
Boston, MA, USA
HybridAt least three days on-site per week required.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • Medical Doctorate (MD or DO).
  • Advanced clinical training in Rheumatology.
  • A minimum of 15 years of previous experience in clinical or related research is preferred.
  • A history of mentoring and/or directly managing individuals in a team-based matrix environment.
  • Familiarity with International Council for Harmonisation, Good Clinical Practice, and relevant regulatory requirements.
  • Experience interacting with medical monitors, development operations, including preclinical, clinical operations, regulatory affairs, and Quality Assurance, and clinical investigators.
  • Strong oral and written communication, analytical, collaborative, and strategic-thinking skills.
Responsibilities
  • Develop the clinical development strategy for the zugocaptagene-geleucel autoimmune program, including early- and late-stage study designs, protocols, investigator brochures, briefing books, regulatory documents, and regulatory interactions.
  • Mentor clinical development leads in developing individual clinical studies aligned with the clinical development plan, including authoring and reviewing protocols, investigator brochures, electronic case report forms, informed consent forms, and clinical study reports.
  • Review clinical trial safety and efficacy data, perform medical monitoring, assess consistency and completeness, and provide assessments and recommendations.
  • Build and maintain relationships with thought leaders, clinical investigators, and partners to inform study design and program direction.
  • Serve as the clinical development lead for one or more studies.
  • Communicate a clear overview of trial results.
  • Collaborate with clinical operations, data management, statistics, safety, commercial, and regulatory affairs stakeholders to translate clinical protocols into operational deliverables.
  • Review and synthesize scientific literature and competitive intelligence to support study and program strategy.
  • Develop scientific and protocol training presentations for internal and external meetings, including site qualification and initiation, investigator meetings, and training materials.
  • Prepare scientific materials for conference presentations and publications.
  • Lead and oversee clinical development leads in authoring and revising regulatory submissions.
  • Perform analyses and generate scientific slide decks based on clinical, translational, and other datasets.
Desired Qualifications
  • Clinical or research experience in autoimmune chimeric antigen receptor T-cell trials.
  • A strong track record of drug development in an industry setting.
  • A proven history of effectively guiding and developing clinical development colleagues.

About the company

C

CRISPR Therapeutics

View
Website

CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 to treat serious diseases. It edits genes in human cells, either ex vivo or in vivo, to correct disease-causing mutations, focusing on sickle cell disease, cancer, and other genetically defined conditions. The company supports its pipeline through partnerships and licensing in addition to internal R&D and clinical work, rather than relying solely on in-house development. Its goal is to deliver durable, disease-modifying therapies that meet unmet medical needs for patients worldwide through a global biopharmaceutical strategy.

Company Size

201-500

Company Stage

IPO

Headquarters

Switzerland

Founded

2013

Get referred to CRISPR Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved CASGEVY for children age 2+, expanding eligibility by roughly 5,500 patients.
  • Germany reimbursement on May 6, 2026 broadens access and supports European uptake.
  • Phase 1 starts for CTX340 and CTX460 create multiple new catalysts in 2026.

What critics are saying

  • CASGEVY revenue was only $76 million in Q2 2026, while losses hit $91.2 million.
  • Broad won another March 2026 PTAB ruling; CRISPR's CRISPR-Cas9 foundation remains legally fragile.
  • If slow patient starts persist through 2027, CRISPR's cash burn outlives CASGEVY commercialization.

What makes CRISPR Therapeutics unique

  • CASGEVY is the first approved CRISPR/Cas9 therapy, with 39-country authorization by August 2026.
  • CRISPR built a deep in vivo pipeline: CTX310, CTX340, CTX321, and CTX460.
  • Vertex partnership monetizes CASGEVY globally, while CRISPR retains exposure to upside royalties.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Hybrid Work Options
  • Stock Options
  • 401(k) Retirement Plan
  • Wellness Program
  • Mental Health Support
  • Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 18th, 2026
Cathie Wood buys $3.4M more CRISPR Therapeutics stock in two days, lifting her stake to $379M

Cathie Wood's Ark Invest bought $3.4 million of CRISPR Therapeutics stock over two days, adding to a stake worth $379.1 million. It bought $1.1 million on October 9 and $2.3 million on October 12 for its ARK Genomic Revolution ETF. The stock is down a little more than 25% over the past year. Casgevy, developed with Vertex Pharmaceuticals, is CRISPR's only approved therapy. It lists at $2.2 million per patient, and Vertex takes 60% of revenue. Casgevy revenue hit $76 million in the second quarter, up 151% year over year. Net loss fell to $91.2 million from $208.5 million, and the company holds $2.36 billion in cash. Its cholesterol therapy CTX-310 cut LDL by 53% in an early trial. A phase 2 readout for blood thinner CTX611 is due later this year.

Yahoo Finance
Sep 14th, 2026
AbbVie's $61B revenue beats CRISPR's gene-editing promise for 2026 investors

AbbVie reported revenue of $61.2 billion in FY 2025, up 8.6% year-over-year, with net income of $4.2 billion. The pharmaceutical giant generated free cash flow of $17.8 billion despite a debt-to-equity ratio of -21.1x. Growth products Skyrizi and Rinvoq are offsetting competition for older medications. CRISPR Therapeutics saw revenue fall 90% to $3.5 million in FY 2025 and posted a net loss of $581.6 million. The gene-editing company burned $345.9 million in cash but maintains a conservative balance sheet with a 0.2x debt-to-equity ratio and 13.3x current ratio. AbbVie faces patent expiry risks and pricing pressures, whilst CRISPR depends heavily on partner Vertex for commercialisation. CRISPR's Casgevy gene therapy recently gained FDA approval for children aged two and above, expanding its patient population.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
CRISPR Therapeutics revenue set to jump to $156M in 2027 as gene therapy uptake accelerates

CRISPR Therapeutics and Viking Therapeutics are two pharmaceutical stocks positioning for growth in 2027. CRISPR's gene-editing sickle cell treatment Casgevy, approved in late 2023, has shown minimal revenue due to its lengthy administration process. Each custom treatment takes roughly a year to complete, and CRISPR only books revenue after the full process finishes. However, partner Vertex Pharmaceuticals facilitated $76 million in Casgevy sales in Q2, up 78% year-over-year. Analysts project CRISPR's revenue will jump from $40 million this year to over $156 million in 2027. Viking Therapeutics is developing VK2735, a monthly GLP-1 weight-loss injection, offering more convenience than competitors like Eli Lilly's Zepbound and Novo Nordisk's Wegovy, which require weekly injections. The company plans to begin late-stage trials of an oral pill version before year-end.

MJH Life Sciences
Sep 5th, 2026
Novartis, BMS pause autoimmune CAR-T trials after safety events.

Novartis, BMS pause autoimmune CAR-T trials after safety events. Novartis suspended several autoimmune and neurology trials of rap-cel after 3 patient deaths linked to immune effector cell-associated hemophagocytic syndrome, and BMS separately paused zola-cel studies after observing inflammatory safety events. Novartis has suspended several autoimmune and neurology trials of its investigational CD19 therapy rapcabtagene autoleucel (rap-cel) after 3 patients died following serious cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS).[1,2] Bristol Myers Squibb has separately paused at least some studies of its own CAR-T candidate, zolacabtagene autoleucel (zola-cel), after observing transient and reversible inflammatory events in its autoimmune development program.[1,2] A Novartis spokesperson confirmed the suspension in a statement, saying the 3 IEC-HS cases led to complications that ultimately proved fatal.[1] The pause affects the phase 2 AUTOGRAPH studies evaluating rap-cel in systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies (NCT06665256), along with phase 1/2 trials in rheumatoid arthritis and Sjogren disease (NCT07048197), generalized myasthenia gravis, and certain types of multiple sclerosis.[1] Studies of rap-cel in cancer are not affected by the pause.[1] Novartis is reviewing safety data as BMS acts out of caution. Novartis said it is analyzing safety data to identify the factors that may have contributed to the fatal complications and is working with independent data monitoring committees on enhanced safety measures, including tighter patient monitoring, earlier identification of adverse events, and improved management strategies.[1] BMS, describing its decision as a step taken out of an abundance of caution, confirmed it is voluntarily pausing at least some zola-cel studies to review clinical data across the therapy's development program.[1,2] The company has ongoing zola-cel trials across several autoimmune indications, including myasthenia gravis, multiple sclerosis, and rheumatoid arthritis, though it remains unclear whether the pause extends to all of them.[1] No deaths have been reported in connection with zola-cel; a single prior case of IEC-HS involving the therapy was described in results published in February from a phase 1 study.[2] "The drug's safety profile remains consistent with the known profile of CAR-T therapies," a BMS spokesperson said.[2] Analysts point to rapid manufacturing as a possible contributing factor. IEC-HS is a rare but serious adverse event previously reported with CD19 and BCMA-directed CAR-T therapies across blood cancer indications.[1] In a note to investors, analysts at William Blair pointed to rapid manufacturing, a feature shared by both rap-cel and zola-cel, as a possible contributor to the safety signals.[1] "Rapid manufacturing could be driving increased cell expansion and the reported toxicities," the analysts wrote, while also noting that indication-specific factors or a patient predisposition to a hyperinflammatory state could be playing a role.[1] The analysts cautioned that it remains difficult to extrapolate this risk to other CAR-T programs in development for autoimmune disease, noting that companies including Autolus, Cabaletta Bio, CRISPR Therapeutics, Kyverna Therapeutics, and Allogene Therapeutics are also developing CD19-directed CAR-T therapies for autoimmune indications.[1] Differentiated safety profiles among these competing programs could offer an advantage if development of the Novartis and BMS therapies remains constrained, according to the analysts.[1] Frequently asked questions. * What prompted Novartis to pause rap-cel trials in autoimmune disease? Three patients died after developing serious immune effector cell-associated hemophagocytic syndrome (IEC-HS) following treatment with rap-cel; the pause does not affect ongoing cancer studies of the therapy. * Why did BMS pause zola-cel studies? BMS voluntarily paused at least some zola-cel trials after observing transient and reversible inflammatory events, describing the move as a precaution while it reviews clinical data across the program; no deaths have been reported. * What might be driving these safety signals? Analysts have pointed to rapid manufacturing, a feature shared by both CAR-T candidates, as a possible contributing factor to increased cell expansion and toxicity, though indication-specific factors or patient predisposition may also play a role.